<DOC>
	<DOCNO>NCT00211796</DOCNO>
	<brief_summary>12-week open label treatment trial divalproex sodium extend release ( Depakote ER ) 10 patient diagnosis autism . Our objective determine well patient tolerate prescribe dos add benefit attribute divalproex sodium ER .</brief_summary>
	<brief_title>Divalproex Sodium ER Adult Autism</brief_title>
	<detailed_description>Based positive research divalproex children/adolescents autism , would like extend research autistic adult high level aggression , irritability , affective instability , agitation . We aim 10 adult autistic patient enrol study treatment aggression/irritability divalproex sodium ER . This open treatment adult patient determine tolerability divalproex sodium well extend release . We propose open label design previous double-blinded study divalproex sodium do child , adult . These result serve pilot data future blind study autistic adult extend release formulation . This naturalistic design allow prior stable ( 3 month ) use concomitant medication . Our objective determine well patient tolerate prescribe dos add benefit attribute divalproex sodium ER .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Meet DSMIV , ADI , ADOS criterion autism spectrum disorder . 2 . Age 1865 . 3 . Be see outpatient 4 . Demonstrate capacity provide authorize informed consent provide consent participation approve surrogate autistic individual ’ behalf 5 . Sexually active female childbearing potential must use acceptable method birth control negative serum pregnancy test prior entry study . 6 . Score least “ 4 ” ( moderately ill ) Clinical Global ImpressionSeverity Scale Autistic Disorder ( CGIAD ) . 7 . Subject meet follow criterion prestudy diagnostic assessment baseline assessment : OASM  6 ( raw score ) . 8 . Subjects stable dose current psychotropic medication least 3 month enter study , understand must remain stable dose throughout trial . If subject choose taper current medication , closely monitor study psychiatrist must medication free 2 week prior begin study . Additionally , subject currently take medication know drug interaction Divalproex Sodium , he/she taper medication supervision study psychiatrist undergo treatment . 1 . Subjects pregnant nursing mother . Sexually active woman childbearing potential use adequate birth control measure . 2 . Subjects active unstable epilepsy . 3 . Subjects follow past present mental disorder : schizophrenia , schizoaffective disorder , bipolar disorder , organic mental disorder . 4 . Subjects serious suicidal risk . 5 . Subjects clinically significant unstable medical illness would contraindicate participation study , include hematopoietic cardiovascular disease , pancreatitis , liver toxicity , polycystic ovary syndrome . 6 . Subjects report history encephalitis , phenylketonuria , tuberous schelrosis , fragile X syndrome , anoxia birth , pica , neurofibromatosis , hypomelanosis Ito , hypothyroidism , Duchenne muscular dystrophy , maternal rubella . 7 . Patients history follow : gastrointestinal , liver , kidney , know condition presently interfere presently absorption , distribution , metabolism , excretion drug . cerebrovascular disease brain trauma clinically significant unstable endocrine disorder , hypo hyperthyroidism recent history presence form malignancy Subjects unstable history seizure participate study . However , subject seizurefree 6 month stable dose anticonvulsant medication divalproex sodium relate formulation ( e.g. , depakene ) may participate , along nonmedicated subject history seizure seizurefree 6 month . Subjects abnormal EEG clinical seizure also eligible . 8 . Treatment within previous 30 day drug know welldefined potential toxicity major organ 9 . Subjects clinically significant abnormality laboratory test physical exam . 10 . Subjects history hypersensitivity severe side effect associate use divalproex sodium , ineffective prior therapeutic trial divalproex sodium ( serum level within range 50100 ug/ml 6 week ) . 11 . Subjects currently take medication know drug interaction Divalproex Sodium ( betamipron , chaparral , cholestyramine , clarithromycin , comfrey , ethosuximide , even primrose , felbamate , fosphenytoin , germander , ginkgo , jin bu huan , kava , mefloquine , panipenem , pennyroyal , primidone , rifampin , rifapentine , zidovudine ) refuse taper medication . 12 . Subjects already treat Divalproex Sodium . 13 . Subjects organic systemic disease patient require therapeutic intervention , otherwise specify , would confound evaluation safety study medication . 14 . Subjects reside remote geographical area regular access transportation clinical facility .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>autism</keyword>
	<keyword>divalproex sodium ER</keyword>
	<keyword>aggression</keyword>
	<keyword>irritability</keyword>
</DOC>